|
 |
|
|
|
|
|
|
|
|
|
|
frequently asked questions
|
|
|
|
|
| Who is OphthalmoPharma?
Founded in 2003, OphthalmoPharma (OPPH) is a private pharmaceutical company specializing in the development of ophthalmology treatments.
What is OphthalmoPharma’s financial history?
OPPH is currently financed by its founders, partners, and a select group of private investors.
What is OphthalmoPharma’s business strategy?
OPPH is seeking to in-license compounds from other companies that have an application in ophthalmology and develop them to their fullest potential. OPPH will then move these compounds through regulatory approval, registration, and distribution.
What are OphthalmoPharma’s primary products?
OPPH’s product pipeline is focused on the development of innovative drugs and medical devices for ophthalmology. The products, which address major unmet medical needs such as dry eye syndrome, glaucoma, and age-related macular degeneration (AMD),
What is OphthalmoPharma’s competitive advantage?
OPPH is unique in its strategy to build partnerships to in-license compounds from other companies. OPPH’s management and Board provide expertise that put the company at the forefront of developments in ophthalmology. Because of these collaborations, OPPH has a uniquely strong proprietary intellectual property portfolio.
Who are Ophthalmopharma’s partners?
OPPH is currently in partnership (link to partnership page) with four companies: CIS Pharma (link), BioCydex (link), Laboratoires SERB (link) and Medipol SA (link). OPPH has development agreements with the University of Lausanne, University of Geneva, the Federal Polytechnic University and has received a CHF 350K grant from the Swiss Center of Technological Innovation (CTI) in collaboration with the Jules Gonin Ophthalmic Hospital and Medipol SA. OPPH also continues to pursue negotiations with prospective partners, creating the possibility for new products that will increase the depth and breadth of our product pipeline.
Who is Ophthalmopharma’s management team? Who serves on its Boards of Directors?
OphthalmoPharma’s Executive Management and Board of Directors (link) are accomplished entrepreneurs, industry leaders, and top scientists with extensive business experience and histories of scientific innovation with commercialization success.
Is the market ready for Ophthalmopharma?
“As the world population ages, an epidemic-like expansion of ocular disease will require new drugs. This expanding market and prevailing pharmaeconomic trends make OPPH an attractive target for investment.” – Dr. Randall Gatz, CSO
| | | | | |
|
|
|